Consistently, zosuquidar reduced PD‐L1 expression under both basal and inducible conditions in NSCLC (NCI‐H1975), ovarian cancer (SKOV3), renal carcinoma (786‐O), and pancreatic cancer (MIA PaCa‐2) (Figure 1C). This evidence concerns the gene CD274 and renal carcinoma.